Global Retirement Partners’s Arcutis Biotherapeutics ARQT Stock Holding History

Global Retirement Partners’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$34.7K	Buy	+1,196	New	+$30.6K	﹤0.01%	2573

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Global Retirement Partners's ARQT Position: Q4 2025 in Review

Global Retirement Partners opened a new position in Arcutis Biotherapeutics (ARQT) in Q4 2025: 1,196 shares worth $34.7K. The stake represents ﹤0.01% of the portfolio and ranks #2573 among its holdings.

283 funds tracked by Wall St. Rank hold ARQT as of Q4 2025.

Global Retirement Partners held 1,196 shares of Arcutis Biotherapeutics worth $34.7K as of Q4 2025.
Arcutis Biotherapeutics was a new Global Retirement Partners position in Q4 2025.
Arcutis Biotherapeutics made up ﹤0.01% of Global Retirement Partners's portfolio in Q4 2025, its #2573 holding.
283 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2025.

Based on Global Retirement Partners's 13F filing for Q4 2025, filed 6 Feb 2026.